EL PASO, TX – via eTeligis - Premier Biomedical, Inc. (OTCQB: BIEI), a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease and traumatic brain injury, announced today that Premier Biomedical will present significantly positive results from duplicated testing on mice at the American Association for Cancer Research annual meeting in San Diego, California on April 5-9, 2014. The results demonstrated statistically significant improvements in survival and a prevention of breast cancer in mice treated with Premier Biomedical's anti-breast cancer treatment compared to both chemotherapy and a non-treated control group.
Dr. Mitchell S. Felder, Chairman of the Scientific Advisory Board of Premier Biomedical, Inc., and a co-author of the work, opined that, "This represents a major step forward in the goal of preventing breast cancer metastasis and defeating cancer in a completely nontoxic manner by utilizing the body's own immune system. The AACR conference is one of the most prestigious venues in the world for presenting cutting-edge cancer research."
The presentation for the Poster Session at the annual conference is being developed by Premier Biomedical and its two established partners in R&D, the University of Texas at El Paso and the Department of Defense, with Center of Expertise at the William Beaumont Army Medical Center. In addition, the University of Pisa of Pisa, Italy and the University of Toronto of Toronto, Canada collaborated in the development of the research.
"We are extremely pleased to see the exciting results of our proprietary breast cancer medication study finally made public via the AACR," stated Premier Biomedical, Inc. CEO William A. Hartman. "These study results provide important pre-clinical validation and peer review for our medication as a successful treatment for breast cancer and help to build a foundation to advance our candidate anti-breast cancer medication toward our internal goal of initiating human clinical trials this year."
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, in collaboration with the University of Texas at El Paso and US Department of Defense, specifically targeting the treatment of Alzheimer's disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in El Paso, Texas, with business offices in Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Contact:
Premier Biomedical, Inc.
info@premierbiomedicalinc.com
SOURCE: Premier Biomedical, Inc.
Associated Documentation:
Link to submission on http://www.eteligis.com
BIEI_2-26-14_LST_ETL.docx
To unsubscribe from any future mailings, please visit: http://www.eteligis.com/MassMailUnsubscribe.aspx
Copyright eTeligis Inc. 2014. All rights reserved.
0 comments:
Post a Comment